Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Further information re Director's share transfer

12 Nov 2014 07:00

RNS Number : 7990W
Angle PLC
12 November 2014
 



For immediate release

12 November 2014

 

ANGLE plc

("ANGLE" or the "Company")

 

Further information re Director's share transfer

 

On 21 October 2014, the Company announced that Andrew Newland, Chief Executive of ANGLE, had agreed to transfer up to 3,500,000 ordinary shares of 10p each in the Company ("Ordinary Shares") as security for a loan facility in connection with his moving house (the "Announcement").

 

Following recent comments in the media relating to the Announcement, the Company wishes to provide the following information.

 

The agreement was entered into with Equity First Holdings LLC ("EFH") (the "Agreement") and, under the Agreement, which is a sale and repurchase agreement intended to provide financing to Andrew Newland, he transferred the legal and beneficial interest in 1,350,000 Ordinary Shares to EFH (the "transferred shares") in return for him receiving a payment from EFH of a sum equal to 62 per cent. of the three-day average mid-price per share (the "Starting Market Price") less a financing arrangement fee of 2 per cent.. Further details of the transfer made are set out below. As the legal and beneficial holder of the transferred shares, EFH may take any action it deems appropriate in relation to the transferred shares and is under no obligation to hold or retain the transferred shares.

 

On the maturity date of the Agreement (27 October 2016), Andrew Newland is contractually obliged to purchase the transferred shares or equivalent Ordinary Shares from EFH at a price equal to 67 per cent. of the Starting Market Price and EFH is contractually obliged to deliver the transferred shares or equivalent Ordinary Shares to Andrew Newland on payment.

 

If, prior to the maturity date, the value of the transferred shares falls to 49.6 per cent. or less of the Starting Market Price, Andrew Newland will be required to transfer further Ordinary Shares or provide cash to cover any difference.

 

The summary below is a clarification and correction of certain information contained in the Announcement. Andrew Newland remains interested in the transferred shares by reason of the repurchase obligation contained in the Agreement. Further announcements will be made if any further Ordinary Shares are transferred pursuant to the Agreement.

 

· Number of Ordinary Shares prior to transfer of shares under facility 7,054,686

· Number of Ordinary Shares transferred to EFH pursuant to the facility (and to be repurchased) to date 1,350,000

· Starting Market Price £0.851

· Number of Ordinary Shares with voting rights held after transactions and as a % of the Company 5,704,686 (12.61%)

· Total interest in Ordinary Shares and as a % of the Company(1) 7,054,686 (15.59%)

 

(1) As stated above, under the Agreement, Andrew Newland has agreed to repurchase the transferred shares or equivalent Ordinary Shares at the end of the two year period at a price calculated by reference to the Starting Market Price. For this reason he continues to have an interest in these Ordinary Shares and they are therefore included in his total interest in Ordinary Shares.

 

 

Garth Selvey, Chairman of ANGLE, commented: "Andrew has entered into this finance arrangement to bridge the purchase and renovation of a new house. Andrew believes strongly in the future value of ANGLE and does not want to sell his shares into the market. This facility enables him to return to his original position once the facility is repaid."

 

 

For further information:

 

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Cenkos Securities

Stephen Keys, Dr Christopher Golden (Nominated adviser)

Andy Roberts, Christian Hobart (Sales)

 

020 7397 8900

Buchanan

Mark Court, Sophie Cowles

020 7466 5000

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDMMMMVZRGDZG
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.